Blincyto 35 mcg lyophilized powder for injection Images
Generic Name: blinatumomab
This medication has been identified as Blincyto 35 mcg lyophilized powder for injection. It is supplied by Amgen Inc.
Blincyto is used in the treatment of Acute Lymphoblastic Leukemia and belongs to the drug class CD19 monoclonal antibodies. Risk cannot be ruled out during pregnancy. Blincyto 35 mcg lyophilized powder for injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
More about Blincyto (blinatumomab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CD19 monoclonal antibodies
- En español
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.